Jazz Pharmaceuticals plc (J7Z.F)
- Previous Close
103.45 - Open
104.30 - Bid 101.80 x 1700
- Ask 102.30 x 1700
- Day's Range
103.80 - 105.10 - 52 Week Range
99.06 - 134.35 - Volume
311 - Avg. Volume
10 - Market Cap (intraday)
6.544B - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
23.17 - EPS (TTM)
4.48 - Earnings Date Aug 6, 2024 - Aug 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
208.50
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
www.jazzpharma.comRecent News: J7Z.F
Performance Overview: J7Z.F
Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: J7Z.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: J7Z.F
Valuation Measures
Market Cap
6.41B
Enterprise Value
10.09B
Trailing P/E
23.17
Forward P/E
5.68
PEG Ratio (5yr expected)
0.80
Price/Sales (ttm)
2.02
Price/Book (mrq)
1.91
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
8.61%
Return on Assets (ttm)
4.07%
Return on Equity (ttm)
9.41%
Revenue (ttm)
3.84B
Net Income Avi to Common (ttm)
330.79M
Diluted EPS (ttm)
4.48
Balance Sheet and Cash Flow
Total Cash (mrq)
1.82B
Total Debt/Equity (mrq)
156.50%
Levered Free Cash Flow (ttm)
1.04B
Research Analysis: J7Z.F
Company Insights: J7Z.F
J7Z.F does not have Company Insights